Safety and the Effects of Isolated Left Ventricular Pacing in Patients With Bradyarrhythmias

Overview

Previous experimental and clinical studies have consistently suggested that right ventricular (RV) apical pacing has important adverse effects. Ventricular pacing, however, is required, and cannot be reduced in many patients with atrioventricular block. The SAFE-LVPACE study is a randomized controlled trial that compare the effects of conventional right ventricular (RV) pacing vs. left ventricular (LV) in patients with AV block.

Full Title of Study: “Randomized Clinical Study to Assess the Safety and the Effects of Isolated Left Ventricular Pacing in Patients With Bradyarrhythmias”

Study Type

  • Study Type: Interventional
  • Study Design
    • Allocation: Randomized
    • Intervention Model: Parallel Assignment
    • Primary Purpose: Treatment
    • Masking: Double (Participant, Outcomes Assessor)
  • Study Primary Completion Date: June 2015

Detailed Description

Over the past several years, there has been growing concern over the significant deleterious effects of RV pacing, including electromechanical dyssynchrony, proarrhythmia and development of heart failure (HF). However, it remains unclear whether pacing-related ventricular dyssynchrony can translate into significant LV structural changes and produce important clinical impairment in an average pacemaker population with compromised AV conduction. Alternatively, left ventricular pacing has been shown to minimize ventricular dyssynchrony and to improve symptoms and prognosis in patients with mild to moderated systolic HF and prolonged QRS duration. This randomized controlled study is been conducted to compare the effects of conventional right ventricular (RV) pacing vs. left ventricular (LV) in patients with AV block. The hypothesis is that isolated LV pacing through the coronary sinus can be used safely and provide greater hemodynamic benefits to patients with AV block and normal ventricular function who require only the correction of heart rate. Specifically, the investigator aims are to evaluate the safety, efficacy and the effects of left ventricular pacing using active-fixation coronary sinus lead-the Attain StarFix® Model 4195 OTW Lead, compared to right ventricular pacing in patients with implantation criteria for conventional pacemaker stimulation.

Interventions

  • Device: Left ventricular pacing through coronary sinus tributaries (Attain StarFix)
    • Left ventricular pacing in patients with bradycardia
  • Device: Right ventricular pacing (Medtronic)
    • Conventional right ventricular pacing in patients with bradycardia.

Arms, Groups and Cohorts

  • Active Comparator: RV Pacing
    • Right ventricular pacing
  • Experimental: LV Pacing
    • Left ventricular pacing through coronary sinus tributaries

Clinical Trial Outcome Measures

Primary Measures

  • Surgical success
    • Time Frame: Participants will be evaluated during the perioperative period and during the hospital stay, an expected average of 2 days
    • Surgical success: absence of complications

Secondary Measures

  • Echocardiographic and Clinical composite
    • Time Frame: Participants will be evaluated at 6 and 24 months after PM implantation
    • Echocardiographic: ventricular dysfunction Clinical composite: all mortality, cardiovascular mortality, hospitalization, heart failure

Participating in This Clinical Trial

Inclusion Criteria

  • Older than 18 years – Pacemaker initial implant by transvenous approach – Presence of AV block – Presence of atrial fibrillation / atrial flutter with slow ventricular response – Left ventricular systolic function > 0.40 – Subject agreed to participate and signed the consent form Exclusion Criteria:

  • Absence of venous access – Impediment of venous access due to presence of intracardiac defects – Impediment of venous access due to presence of tricuspid valve prosthesis – Need for radiotherapy in the chest – Presence of chest deformity – Pregnancy – Life expectancy of less than one year – Contraindication to administration of iodinated contrast (creatinine > 3.0) Unable to attend the follow-up appointments

Gender Eligibility: All

Minimum Age: 18 Years

Maximum Age: 90 Years

Are Healthy Volunteers Accepted: No

Investigator Details

  • Lead Sponsor
    • University of Sao Paulo
  • Collaborator
    • Duke University
  • Provider of Information About this Clinical Study
    • Principal Investigator: Roberto Costa, Associated Professor of Cardiovascular Surgery, MD PhD – University of Sao Paulo
  • Overall Official(s)
    • Roberto Costa, MD PhD, Principal Investigator, University of Sao Paulo
  • Overall Contact(s)
    • Roberto Costa, MD PhD, 55-11-2661, rcosta@incor.usp.br

Clinical trials entries are delivered from the US National Institutes of Health and are not reviewed separately by this site. Please see the identifier information above for retrieving further details from the government database.

At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.